# Sprouted Wheat Improves Liver Metabolism and Inflammation in T2DM Mice: 16S rRNA Gene Sequence, Metabolomics and Network Pharmacology Joint Analysis

**Authors:** Xue Gao, Qifang Guo, Peihua Li, Yanquan Mu, Huajing Gao, Qinglin Qu, Jiaqi Liu, Fan Yang, Dapeng Li, Feng Li, Xintong Tan

PMC · DOI: 10.3390/foods15061027 · 2026-03-15

## TL;DR

Sprouted wheat helps improve liver function and reduce inflammation in diabetic mice, possibly through changes in gut bacteria and metabolic pathways.

## Contribution

This study reveals how sprouted wheat improves T2DM via gut microbiota and liver metabolism using multi-omics and network pharmacology.

## Key findings

- Sprouted wheat improved glycolipid metabolism and reduced liver injury in T2DM mice.
- Sprouted wheat altered gut microbiota and inhibited the TLR4/NF-κB inflammatory pathway.
- Five key metabolites and four core targets were identified as mediators of sprouted wheat's protective effects.

## Abstract

Type 2 diabetes mellitus (T2DM) has become a global metabolic disorder, and sprouted wheat (SW) exhibits potential for alleviating metabolic syndromes, although its mechanism remains unclear. This study aimed to investigate the effects and underlying mechanisms of SW on T2DM using a high−fat diet−induced T2DM mouse model. SW intervention significantly improved glycolipid metabolism disorders (p < 0.05), attenuated hepatic mitochondrial injury (p < 0.05) and maintained hepatic homeostasis. SW also reshaped the gut microbiota structure and inhibited the TLR4/NF−κB inflammatory pathway (p < 0.05). Untargeted metabolomics combined with network pharmacology identified five key functional metabolites and four core targets involved in the protective effects of SW. Germination optimized the nutritional composition of wheat, and SW regulated the microbe–liver axis through a multi−component, multi−target and multi-pathway mode. These results reveal the mechanism of SW in improving T2DM−related metabolic disorders and provide experimental support for its application. In the future, SW can be further developed as a dietary nutritional supplement for the prevention and adjuvant treatment of metabolic diseases.

## Linked entities

- **Genes:** TLR4 (toll like receptor 4) [NCBI Gene 7099], NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790]
- **Diseases:** Type 2 diabetes mellitus (MONDO:0005148), T2DM (MONDO:0005148)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** Nfkb1 (nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105) [NCBI Gene 18033] {aka NF-KB1, NF-kappaB, NF-kappaB1, p105, p50, p50/p105}, Tlr4 (toll-like receptor 4) [NCBI Gene 21898] {aka Lps, Ly87, Ran/M1, Rasl2-8}
- **Diseases:** T2DM (MESH:D003924), metabolic diseases (MESH:D008659), hepatic mitochondrial injury (MESH:D056486), Inflammation (MESH:D007249), metabolic syndromes (MESH:D024821)
- **Chemicals:** glycolipid metabolism disorders (-)
- **Species:** Mus musculus (house mouse, species) [taxon 10090]

## Figures

9 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13025019/full.md

---
Source: https://tomesphere.com/paper/PMC13025019